Circulating tumor DNAs and non-coding RNAs as potential biomarkers for hepatocellular carcinoma diagnosis, prognosis and response to therapy

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide and despite improvement in therapeutic approaches, prognosis remains poor. This can be partly attributed to the fact that the majority of HCCs are diagnosed at intermediate or advanced stages. Availability of circulating biomarkers able to detect HCC at early stages could improve patients’ prognosis. At present, however, alpha fetoprotein or des-g-carboxyprothrombin are unable to reliably detect HCC at early stages and better circulating biomarkers are needed. Circulating tumor DNA (ctDNA) and non-coding RNAs (ncRNAs) are emerging as promising biomarkers to achieve the goal. Genetic and epigenetic alterations in ctDNA allow to pinpoint tumor-specific biomarkers, reveal tumor heterogeneity, help monitor tumor evolution over time and assess therapy efficacy. It remains to be fully evaluated the possibility of detecting these biomarkers at early tumor stages. Circulating ncRNAs are quantitative biomarkers with potential use in diagnostic, prognostic and predictive clinical settings. They may help to reveal HCC at early stages. However, because of heterogeneous and sometimes conflicting reported results, they still require validation and standardization of pre-analytical and analytical approaches before clinical applications could be envisaged.

Keywords

Liquid biopsy / hepatocellular carcinoma / circulating tumor DNA / non-coding RNA / diagnosis / prognosis / therapy response

References

[1] Llovet JM,Bruix J.The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma..Liver Transpl2004;10:S115-20

[2] Tabrizian P,Shrager B,Roayaie S.Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis..Ann Surg2015;261:947-55

[3] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[4] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival..Hepatology2003;37:429-42

[5] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[6] Spangenberg HC,Blum HE.Serum markers of hepatocellular carcinoma..Semin Liver Dis2006;26:385-90

[7] Marrero JA,Wang Y,Befeler AS.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma..Gastroenterology2009;137:110-8 PMCID:PMC2704256

[8] McMahon BJ,Harpster A,Lanier A.Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study..Hepatology2000;32:842-6

[9] Chen JG,Chen QG,Shen QJ.Screening for liver cancer: results of a randomised controlled trial in Qidong, China..J Med Screen2003;10:204-9

[10] Volk ML,Su GL,Marrero JA.Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3..Cancer Biomark2007;3:79-87

[11] Grizzi F,Hamrick C,Cobos E.Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma..J Transl Med2007;5:3 PMCID:PMC1797003

[12] Marrero JA,Wei W,Conjeevaram HS.Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients..Hepatology2003;37:1114-21

[13] Llovet JM,Pikarsky E,Schwartz M.Hepatocellular carcinoma..Nat Rev Dis Primers2016;2:16018

[14] Lamerz R,Stieber P.Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases..Anticancer Res1999;19:2489-93

[15] Yan L,Zhou J,Zhang H.Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma..Int J Infect Dis2018;67:92-7

[16] Iizuka N,Moribe T,Miura T.Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma..Anticancer Res2006;26:4713-9

[17] Tokuhisa Y,Sakaida I,Fujita N.Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma..Br J Cancer2007;97:1399-403 PMCID:PMC2360234

[18] Piciocchi M,Vitale A,Giacomin A.Circulating free DNA in the progression of liver damage to hepatocellular carcinoma..Hepatol Int2013;7:1050-7

[19] Park S,Rim CH.Plasma cell-free DNA as a predictive marker after radiotherapy for hepatocellular carcinoma..Yonsei Med J2018;59:470-9 PMCID:PMC5949288

[20] Zhang C,Huang T,Dai D.Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma..Oncotarget2016;7:81255-67 PMCID:PMC5348390

[21] Huang ZH,Hua D,Song MX.Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma..Exp Mol Pathol2011;91:702-7

[22] Hua D,Wu YY,Yu J.Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma..Exp Mol Pathol2011;91:455-60

[23] Wong IH,Yeo W,Johnson PJ.Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients..Clin Cancer Res2000;6:3516-21

[24] Wei L,Zhao R,Liu Q.Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases..Clin Exp Med2018;18:79-87

[25] Holmila R,Muller DC,Guilloreau P.Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma..PLoS One2017;12:e0174265 PMCID:PMC5363871

[26] Marchio A,Béré A,Noah Noah D.Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma..Clin Exp Med2018;18:421-31

[27] Labgaa I,D’Avola D,von Felden J.A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma..Oncogene2018;37:3740-52 PMCID:PMC6035113

[28] Huang A,Zhou SL,Huang XW.Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity..J Cancer2016;7:1907-14 PMCID:PMC5039376

[29] Ikeda S,Kurzrock R.Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma: implications for targeted therapeutics..Mol Cancer Ther2018;17:1114-22 PMCID:PMC5932233

[30] Lim HY,Choi HJ,Yoon JH.A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma..Clin Cancer Res2014;20:5976-85

[31] Lim HY,Weiss KH,Ross P.Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma..Clin Cancer Res2018;24:4650-61

[32] Cai ZX,Zeng YY,Lin MJ.Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma..Int J Cancer2017;141:977-85

[33] Negrini M,Sabbioni S.MicroRNAs in human cancer: from research to therapy..J Cell Sci2007;120:1833-40

[34] Lawrie CH,Dunlop HM,Liggins AP.Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma..Br J Haematol2008;141:672-5

[35] Mitchell PS,Kroh EM,Wyman SK.Circulating microRNAs as stable blood-based markers for cancer detection..Proc Natl Acad Sci U S A2008;105:10513-8 PMCID:PMC2492472

[36] Thomson JM,Hammond SM.Microarray analysis of miRNA gene expression..Methods Enzymol2007;427:107-22

[37] Miotto E,Lupini L,Negrini M.Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries..Cancer Epidemiol Biomarkers Prev2014;23:2638-42

[38] Wojcicka A,Kornasiewicz O,Maciag M.Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma..Int J Biochem Cell Biol2014;53:208-17

[39] Dingle TC,Cook L.Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances..Clin Chem2013;59:1670-2 PMCID:PMC4247175

[40] Hindson CM,Briggs HA,Ruf IK.Absolute quantification by droplet digital PCR versus analog real-time PCR..Nat Methods2013;10:1003-5 PMCID:PMC4118677

[41] Mangolini A,Zanzi MV,Ebnaof SO.Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR..Biomark Res2015;3:12 PMCID:PMC4483205

[42] Heegaard NH,Welsh JA,Bowman ED.Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer..Int J Cancer2012;130:1378-86 PMCID:PMC3259258

[43] Giray BG,Tezcan S,Serin MS.Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma..Mol Biol Rep2014;41:4513-9

[44] Oksuz Z,Kaplan E,Tezcan S.Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma..Mol Biol Rep2015;42:713-20

[45] Qi P,Wang H,Chen YF.Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection..PLoS One2011;6:e28486 PMCID:PMC3234251

[46] Xu J,Che X,Yu D.Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis..Mol Carcinog2011;50:136-42

[47] Ge W,Li QG,Zhang CY.Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances..Clin Lab2014;60:427-34

[48] Tomimaru Y,Nagano H,Kobayashi S.Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma..J Hepatol2012;56:167-75

[49] Zhou J,Gao X,Wang J.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma..J Clin Oncol2011;29:4781-8

[50] Zuo D,Liu X,Xi Q.Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma..Tumour Biol2016;37:6539-49

[51] Moshiri F,Gramantieri L,Guerriero P.Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma..Oncotarget2018;9:15350-64 PMCID:PMC5880609

[52] Zhuang C,Huang D,Yang Q.Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma..Clin Res Hepatol Gastroenterol2016;40:386-96

[53] Xie Y,Butt AM,Tian Z.Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma..Cancer Biol Ther2014;15:1248-55 PMCID:PMC4128867

[54] Pritchard CC,Wood B,Dougherty KJ.Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies..Cancer Prev Res (Phila)2012;5:492-7 PMCID:PMC4186243

[55] Zheng XH,Zhou XX,Jia WH.Centrifugation: an important pre-analytic procedure that influences plasma microRNA quantification during blood processing..Chin J Cancer2013;32:667-72 PMCID:PMC3870851

[56] El-Garem H,Shehab H,Anwer M.Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma..World J Hepatol2014;6:818-24 PMCID:PMC4243156

[57] Fornari F,Trerè D,Marinelli S.Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC..PLoS One2015;10:e0141448 PMCID:PMC4624953

[58] Chen S,Gao S,Zhou H.Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma..Hepatol Res2017;47:312-20

[59] Guo X,Lv X,Chen L.Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis..Oncotarget2017;8:44050-8 PMCID:PMC5546461

[60] Zekri AN,El-Desouky ED,Lotfy MM.Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection..Tumour Biol2016;37:12273-86

[61] Tat Trung N,Tong HV,Hoan PQ.Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma..PLoS One2018;13:e0196081 PMCID:PMC5908085

[62] Jarry J,Greenwood C,van Kempen LC.The validity of circulating microRNAs in oncology: five years of challenges and contradictions..Mol Oncol2014;8:819-29 PMCID:PMC5528532

[63] Cookson VJ,Hogan BV,Hayward BE.Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours..Cell Oncol (Dordr)2012;35:301-8

[64] McAllister SS.The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis..Nat Cell Biol2014;16:717-27 PMCID:PMC6220424

[65] Su H,Xu T,Xu L.MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity..Cancer Res2009;69:1135-42

[66] Volinia S,Liu CG,Cimmino A.A microRNA expression signature of human solid tumors defines cancer gene targets..Proc Natl Acad Sci U S A2006;103:2257-61 PMCID:PMC1413718

[67] Meng FL,Jia WD.Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma..Med Oncol2014;31:177

[68] Zhang JP,Xu L,Fang JH.MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling..Oncogene2014;33:4069-76

[69] Huang J,Guo Y.Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1..Hepatology2010;52:60-70

[70] Zhang JG,Hong DF,Huang D.MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/beta-catenin pathway..Sci Rep2015;5:8087 PMCID:PMC4310092

[71] Wang F,He B,Sun H.Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma..Tumour Biol2016;37:4945-53

[72] Li J,Yu W,Luo J.Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance..Biochem Biophys Res Commun2011;406:70-3

[73] Yang L,Xie H,Jiang J.Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance..Clin Transl Oncol2016;18:841-7

[74] Qu Z,Wu J,Qiang G.Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis..Oncotarget2017;8:80666-78 PMCID:PMC5655229

[75] Shi M,Yang L,Wang YG.Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma..J Cell Biochem2018;119:4711-6

[76] Zheng J,Xu Z,Dong P.Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression..Mol Med Rep2015;12:1584-90

[77] Liu W,Zhou K,Wang Z.Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma..Onco Targets Ther2017;10:3843-51 PMCID:PMC5546809

[78] Wang H,Li A,Gao H.Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma..Biomed Res Int2014;2014:864894 PMCID:PMC4052145

[79] Wang X,Zhou L,Zheng ZG.Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model..Int J Clin Exp Pathol2015;8:1466-78 PMCID:PMC4396214

[80] Lee YR,Tak WY,Kweon YO.Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma..Int J Cancer2018;

[81] Liver EAftSotEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[82] Ng KT,Wong N,Qi X.Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation..Oncotarget2016;7:19824-39 PMCID:PMC4991421

[83] European Association for Study of L, European Organisation for R, Treatment of CEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..Eur J Cancer2012;48:599-641

[84] Kim SS,Cho HJ,Kim JW.Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma..J Gastroenterol Hepatol2017;32:199-207

[85] Suehiro T,Kanda Y,Honda T.Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients..Oncol Lett2018;16:3267-73 PMCID:PMC6096216

[86] Cui L,Bai B.Serum miR-335 Level is Associated with the Treatment Response to Trans-Arterial Chemoembolization and Prognosis in Patients with Hepatocellular Carcinoma..Cell Physiol Biochem2015;37:276-83

[87] Liu M,Wang L,Zhou C.Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival..PLoS One2014;9:e109347 PMCID:PMC4183700

[88] Fornari F,Patrizi C,Marinelli S.In hepatocellular carcinoma miR-221 modulates Sorafenib resistance through inhibition of caspase-3 mediated apoptosis..Clin Cancer Res2017;

[89] Nishida N,Hagiwara S,Sakurai T.MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma..Liver Cancer2017;6:113-25 PMCID:PMC5340220

[90] Geisler S.RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts..Nat Rev Mol Cell Biol2013;14:699-712 PMCID:PMC4852478

[91] Ransohoff JD,Khavari PA.The functions and unique features of long intergenic non-coding RNA..Nat Rev Mol Cell Biol2018;19:143-57 PMCID:PMC5889127

[92] Hauptman N.Long non-coding RNA in cancer..Int J Mol Sci2013;14:4655-69 PMCID:PMC3634483

[93] Tang Y,Atmadibrata B,Dinger ME.The regulatory role of long noncoding RNAs in cancer..Cancer Lett2017;391:12-9

[94] DiStefano JK.Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma..Noncoding RNA Res2017;2:129-36 PMCID:PMC6084840

[95] Lu J,Geng L,Sui C.Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV..Tumour Biol2015;36:3231-6

[96] Xu H,Dong X.Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma..Cancer Epidemiol Biomarkers Prev2018;27:710-6

[97] Gao S,Wang Y,Wang X.Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with hepatocellular carcinoma..Mol Med Rep2018;18:3305-13 PMCID:PMC6102699

[98] Luo P,Zhang X,Wang Y.Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of HCC..Biosci Rep2018;38: PMCID:PMC6050191

[99] Kamel MM,Sallam M,Saad AS.Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma..Transl Res2016;168:134-45

[100] Yu J,Zhang J,Liu H.The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis..Medicine (Baltimore)2016;95:e4436 PMCID:PMC4979822

[101] Ma W,Jing W,Chang L.Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma..Clin Res Hepatol Gastroenterol2017;41:163-70

[102] Wang ZF,Pang JM,Yan W.Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma..Oncol Lett2018;16:1593-601 PMCID:PMC6036462

[103] Zheng ZK,Yang Y,Zhang J.Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma..J Int Med Res2018;46:348-56 PMCID:PMC6011314

[104] Li J,Tang J,Zhang W.HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma..Cell Physiol Biochem2015;37:687-96

[105] Ma X,Yang C,Han B.DANCR Acts as a Diagnostic Biomarker and Promotes Tumor Growth and Metastasis in Hepatocellular Carcinoma..Anticancer Res2016;36:6389-98

[106] Li J,Kan A,Huang L.SNHG and UCA1 as prognostic molecular biomarkers in hepatocellular carcinoma: recent research and meta-analysis..Minerva Med2017;108:568-74

[107] Xie Z,Yang Y,Lei Y.Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma..EBioMedicine2018;33:57-67 PMCID:PMC6085584

[108] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[109] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma..N Engl J Med2018;379:54-63

[110] Hindson BJ,Masquelier DA,Heredia NJ.High-throughput droplet digital PCR system for absolute quantitation of DNA copy number..Anal Chem2011;83:8604-10 PMCID:PMC3216358

[111] Ferracin M,Salamon I,Zanzi MV.Absolute quantification of cell-free microRNAs in cancer patients..Oncotarget2015;6:14545-55 PMCID:PMC4546486

[112] Witwer KW.Circulating microRNA biomarker studies: pitfalls and potential solutions..Clin Chem2015;61:56-63

[113] Lu LC,Hsu C.Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges..Liver Cancer2016;5:128-38 PMCID:PMC4906428

[114] Chen K,Zhang LN,Qi J.Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma..World J Gastroenterol2013;19:3143-9 PMCID:PMC3662956

[115] Ren N,Qin LX,Liu YK.Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients..World J Gastroenterol2006;12:3911-4 PMCID:PMC4087944

[116] Iyer P,Hung CW,Ismail K.Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients..Exp Mol Pathol2010;88:107-11 PMCID:PMC4512240

[117] Oussalah A,Bensenane M,Filhine-Tresarrieu P.Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma..EBioMedicine2018;30:138-47 PMCID:PMC5952996

[118] Hu N,Fan YC,Qiao CY.Hypomethylated Ubiquitin-Conjugating Enzyme2 Q1 (UBE2Q1) Gene Promoter in the Serum Is a Promising Biomarker for Hepatitis B Virus-Associated Hepatocellular Carcinoma..Tohoku J Exp Med2017;242:93-100

[119] Jiao J,Stevenson HL,Fisher-Hoch SP.Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors..Hepatol Commun2018;2:718-31 PMCID:PMC5983165

[120] Liao W,Xu H,Ge P.Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing..Oncotarget2016;7:40481-90 PMCID:PMC5130021

[121] Garcia-Fernandez N,Rubio A,Bernal-Bellido C.Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence..Adv Exp Med Biol2016;924:25-8

[122] Xu H,Xu Z,Bo S.Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular Carcinoma by Next Generation DNA Sequencing..J Cancer2015;6:247-53 PMCID:PMC4317760

[123] Chan KC,Zheng YW,Sun H.Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing..Clin Chem2013;59:211-24

[124] Liu AM,Wang W,Lee NP.Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study..BMJ Open2012;2:e000825 PMCID:PMC3308260

[125] Zhu HT,Liu RB,Zhang X.Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma..Oncotarget2016;7:45637-48 PMCID:PMC5216748

[126] Fu Y,Tang C,Liu R.Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma..Oncol Lett2013;6:1811-5 PMCID:PMC3834113

[127] Sohn W,Kang SH,Cho JY.Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma..Exp Mol Med2015;47:e184 PMCID:PMC4650928

[128] Huang JT,Ma H,Zhang X.Systematic Review and Meta-Analysis: Circulating miRNAs for Diagnosis of Hepatocellular Carcinoma..J Cell Physiol2016;231:328-35

[129] Hung CH,Lu SN,Chen CH.Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus..Int J Cancer2016;138:714-20

[130] Luo J,Huang H,Zhang M.Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma..Onco Targets Ther2013;6:577-83 PMCID:PMC3666878

[131] Fang T,Lv G,Wang C.Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer..Nat Commun2018;9:191 PMCID:PMC5768693

[132] Zhang J,Wang XY,Chen JX.Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma..Cancer Biomark2017;19:257-62

[133] Zhao Q,Liu C,Cui J.Expression of the microRNA-143/145 cluster is decreased in hepatitis B virus-associated hepatocellular carcinoma and may serve as a biomarker for tumorigenesis in patients with chronic hepatitis B..Oncol Lett2018;15:6115-22 PMCID:PMC5876422

[134] Qu KZ,Li H,Albitar M.Circulating microRNAs as biomarkers for hepatocellular carcinoma..J Clin Gastroenterol2011;45:355-60

[135] Chen L,Cao Y,Wang F.Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma..Tumour Biol2015;36:7439-47

[136] Amr KS,Elhosary YA,Fahim HH.The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma..Gene2016;575:66-70

[137] Bihrer V,Friedrich-Rust M,Susser S.Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma..PLoS One2011;6:e26971 PMCID:PMC3205002

[138] Li F,Zhu C,Zhang T.miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker..Int J Nanomedicine2018;13:2295-307 PMCID:PMC5907790

[139] Bhattacharya S,Shrivastava S,Di Bisceglie AM.Serum miR-30e and miR-223 as novel noninvasive biomarkers for hepatocellular carcinoma..Am J Pathol2016;186:242-7 PMCID:PMC4729242

[140] Okajima W,Ichikawa D,Kawaguchi T.Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function..Oncotarget2016;7:53820-36 PMCID:PMC5288224

[141] Lin XJ,Guo ZW,Yang XJ.A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study..Lancet Oncol2015;16:804-15

[142] Gui J,Wen X,Zhang P.Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies..Clin Sci (Lond)2011;120:183-93 PMCID:PMC2990200

[143] Chen Y,Yu D.Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection..Int J Clin Exp Med2015;8:18462-8 PMCID:PMC4694353

[144] Zheng F,Cai MY,Chen SP.Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets..PLoS Genet2015;11:e1004873 PMCID:PMC4334495

[145] Xu Y,Dai C.High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients..Tumour Biol2015;36:4773-6

[146] Zhuang LP.Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival..Biomed Res Int2015;2015:731781 PMCID:PMC4320918

[147] Cho HJ,Nam JS,Lee JH.High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation..Clin Biochem2015;48:1073-8

[148] Kim SS,Nam JS,Kang DR.Plasma MicroRNA-21, 26a, and 29a-3p as predictive markers for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma..J Korean Med Sci2018;33:e6 PMCID:PMC5729641

[149] Cho HJ,Nam JS,Lee JH.Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment..Clin Res Hepatol Gastroenterol2017;41:181-9

[150] Xiang ZL,Zhang L,Fan J.MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma..Oncotarget2016;7:87246-56 PMCID:PMC5349985

[151] Sugimachi K,Hirata H,Ueda M.Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation..Br J Cancer2015;112:532-8 PMCID:PMC4453648

[152] Stiuso P,Lombardi A,Monaco A.MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib..Mol Ther Nucleic Acids2015;4:e233

[153] El-Tawdi AH,Shehata HH,El-Khazragy N.Evaluation of circulatory RNA-based biomarker panel in hepatocellular carcinoma..Mol Diagn Ther2016;20:265-77

[154] Xie H,Zhou D.Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma..Biomed Res Int2013;2013:136106 PMCID:PMC3674644

[155] El-Tawdi AH,El-Nakeep S,Abdel-Rahman O.Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma..Expert Rev Gastroenterol Hepatol2016;10:869-77

[156] Tang J,Zhang X,Ji J.A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma..Cell Death Dis2014;5:e1549 PMCID:PMC4649834

[157] Wang X,Tang J,Li J.LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway..Cell Death Dis2016;7:e2130 PMCID:PMC4823934

[158] Tang J,Deng L,Wang K.Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma..Oncotarget2015;6:4505-15 PMCID:PMC4414207

[159] Konishi H,Yamamoto Y,Shoda K.Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma..Cancer Sci2016;107:149-54 PMCID:PMC4768388

[160] Jing W,Zhu M,Jing X.Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma..Oncol Rep2016;36:1085-92

[161] Wang K,Li N,Shi J.Serum LncRNAs profiles serve as novel potential biomarkers for the diagnosis of HBV-positive hepatocellular carcinoma..PLoS One2015;10:e0144934 PMCID:PMC4684503